Year: 2019

TAALERI OYJ     JOHDON LIIKETOIMET    9.12.2019 KLO 15:05IlmoitusvelvollinenNimi: Koikkalainen JanneAsema: Muu ylin johto(X) OikeushenkilöLiikkeeseenlaskija: Taaleri OyjLEI: 743700LSJBDD7TMLAD92Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700LSJBDD7TMLAD92_20191205132329_2____________________________________________Liiketoimen päivämäärä: 2019-12-05Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Instrumenttityyppi: OSAKEISIN: FI4000062195Liiketoimen luonne: LUOVUTUSLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 10 000 Yksikköhinta: 7,37 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 10 000 Keskihinta: 7,37 EURTaaleri Oyj ViestintäSophie Jolly, Viestintä- ja sijoittajasuhdejohtaja, puh. 040 828 7317, sophie.jolly@taaleri.com

TAALERI PLC    MANAGERS’ TRANSACTIONS    9 DECEMBER 2019 AT 3:05 PM (EET)Person subject to the notification requirementName: Koikkalainen JannePosition: Other senior manager(X) Legal personIssuer: Taaleri OyjLEI: 743700LSJBDD7TMLAD92Notification type: INITIAL NOTIFICATIONReference number: 743700LSJBDD7TMLAD92_20191205132329_2____________________________________________Transaction date: 2019-12-05Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000062195Nature of the transaction: DISPOSALTransaction details(1): Volume: 10,000 Unit price: 7.37 EURAggregated transactions(1): Volume: 10,000 Volume weighted average price: 7.37 EURTaaleri PlcCommunicationsSophie Jolly, Head of Communications and IR, tel. +358 40 828 7317, sophie.jolly@taaleri.com

– Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ETNorwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will host a symposium on the endocannabinoid system (“ECS”) and the therapeutic potential of targeting the ECS. The symposium will be webcasted live (details below) on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET.Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will host the event, and Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus will moderate the panel session. The panel session will feature presentations from the following experts:Webcast DetailsInterested...

Presentation on Tuesday, December 10th at 4:20 PM PST / 7:20 PM ESTLOS ANGELES, CA, Dec. 09, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced that it will be presenting at the 6th annual LD Micro Invitational on Tuesday, December 10th at 4:20 PM PST/7:20 PM EST. The conference will feature 195 companies in the small and micro-cap space and will be held at the Luxe Sunset Bel Air Hotel.Dr. Ernest Bates, Chairman and CEO, Craig Tagawa, COO and CFO, and Ernest R. Bates, Vice President of Sales and Business Development, will be giving the presentation and meeting with investors. The Company’s Controller Alexis Wallace will also be in...

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechanism of action for its lead asset, Plinabulin, have been accepted as e-publications at this year’s American Society of Hematology’s (ASH) Annual Meeting, taking place on December 7 through 10 in Orlando, Fla.The first abstract, titled, “Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin’s Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN),” involves BeyondSpring’s Study 105 and highlights Plinabulin’s ability to protect GMP, a hematopoietic stem cell which differentiates into neutrophils...

Southfield, Michigan, Dec. 09, 2019 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that it has commenced a cash tender offer (the “Offer”) for any and all of the $300,000,000 aggregate principal amount of its 6.125% Senior Notes due 2021 with CUSIP number 225310AG6 (the “Notes”).The Offer will expire at 5:00 P.M., New York City time, on December 13, 2019 unless extended (such date and time, as the same may be extended, the “Expiration Time”). Holders who validly tender (and do not validly withdraw) their Notes at or before the Expiration Time will receive $1,002.80 for each $1,000 principal amount of Notes accepted for purchase. Accrued and unpaid interest up to, but not including, the payment date, which is expected to be December...

Please find attached the minutes of the EGM held on 9th December 2019.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentSSC Plc EGM minutes

Chicago, Dec. 09, 2019 (GLOBE NEWSWIRE) — PureCircle (LSE: PURE), the world’s leading producer and innovator of great-tasting stevia ingredients for the global beverage and food industries, announces several important new developments which will further support its customers in their creation of zero-added sugar and reduced-sugar products.  PureCircle is now introducing a new stevia ingredient, which will be extremely valuable to beverage and food companies.  Called Sigma Syrup, this optimized blend of our next generation stevia leaf ingredients, including Reb M, is proprietary to PureCircle. Sigma Syrup provides superior taste and overcomes solubility challenges encountered when using other stevia sweeteners in products which are high in sweetness intensity, such as syrups and liquid tabletop sweeteners.  Sigma Syrup is made...

WASHINGTON, Dec. 09, 2019 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that its Technology segment has launched a new set of managed e-discovery services using Brainspace, a leading data analytics platform for investigations, e-discovery, intelligence mining and compliance. In partnership with Brainspace, FTI Technology has integrated its platform as part of the firm’s e-discovery managed services solution to help clients strengthen early case assessments and handle the growing volume and complexity of legal review and investigations.“Advanced analytics have become a critical component of the toolset needed to efficiently and defensibly fulfill e-discovery obligations for matters of all sizes,” said Daryl Teshima, a Senior Managing Director within FTI Technology. “Because every matter is different, we take...